Perseus Proteomics Inc.

Founded in 2001 and based in Tokyo, Japan, Perseus Proteomics Inc. is a drug discovery bio-venture company that provides new medical care modalities by employing cutting-edge antibody technologies to develop antibody drugs. The company was established based on the technologies of protein expression and antibody generation, which were developed by the Laboratories for Systems Biology and Medicine (LSBM) of the Research Center for Advanced Science and Technology at the University of Tokyo, aiming at the medical application of antibodies against the diagnostic and therapeutic targets identified through transcriptome analysis. In 2004, the company signed a distributorship agreement with R&D Systems Inc.

for the distribution of its research reagents in the United States and initiates global sales. In 2006, the Company signed an agreement with Chugai Pharmaceutical Co. , Ltd. for the transfer of rights for the therapeutic use of the anti-glypican 3 antibodies “anti-hepatocarcinoma antibody (PPMX-T001).

” From 2019 to 2020, the Company began a phase I clinical trial of the anti-transferrin receptor antibody (PPMX-T003) as an anticancer drug, and a phase I clinical trial of the radioisotope (RI)-labeled antibody (PPMX-T002) as an anticancer drug in Japan. The company uses its proprietary technology to develop functional antibodies and use them as therapeutics. It also conducts research and development to enhance the potency of attacking cancer cells by the chemically conjugating radioisotope or toxins to those therapeutic antibodies. The company will continue to develop new antibody-drug to cure various cancers by using the latest word antibody technology.